Management of children with hereditary angioedema due to C1 inhibitor deficiency

US Hereditary Angioedema Association Medical Advisory Board

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Hereditary angioedema (HAE) is a potentially life-threatening inherited disease characterized by attacks of skin swelling, severe abdominal pain, and upper airway swelling. Attacks typically begin in childhood, but the appropriate diagnosis is often missed. Attacks do not respond to epinephrine, antihistamines, or glucocorticoids. Recently, many effective drugs have been approved for treatment of adults with HAE, and the Medical Advisory Board of the HAE Patient's Association has developed and reported treatment recommendations for adults. Only 1 medication is approved for treatment of children <12 years of age, and there are no reported consensus recommendations for treatment of young children in the United States. The 11-member Medical Advisory Board, with extensive experience in the treatment of children, in concert with the leaders of the HAE Patient's Association, has developed these consensus recommendations to help in recognition, diagnosis, treatment of attacks, and prophylaxis of children with HAE.

Original languageEnglish (US)
Article numbere20160575
JournalPediatrics
Volume138
Issue number5
DOIs
StatePublished - Nov 2016

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Management of children with hereditary angioedema due to C1 inhibitor deficiency'. Together they form a unique fingerprint.

  • Cite this

    US Hereditary Angioedema Association Medical Advisory Board (2016). Management of children with hereditary angioedema due to C1 inhibitor deficiency. Pediatrics, 138(5), [e20160575]. https://doi.org/10.1542/peds.2016-0575